The Global Leukemia Therapeutics anticipated to have held a market value of USD 10.7 billion in the year 2017 and is expected to grow at a CAGR of 5.3% during the forecast period. Leukemia is blood cancer which most commonly in adults and children. Acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia are the major types of the leukemia. leukemia therapeutics such as chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant are used in treating the leukemia.
Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/7425
Availability of innovative therapies for leukemia, increasing number of cases of leukemia, strong developing pipeline and targeted drug delivery, and increasing older population are expected to drive the growth of market. According to the Leukemia & Lymphoma Society of Canada, in 2016 estimated 22,510 were suffer with leukemia in Canada and 5,900 new cases of leukemia founded in same year. On other hand, high cost required for the development of new therapeutics can restrain the market growth over the assessment period.
Segmentation
The global leukemia therapeutics market has been segmented into type, applications, and region.
Based on applications, leukemia therapeutics market is segmented into acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and others. The acute lymphocytic leukemia segment is expected to account for the largest share segment of the market in 2017.
Based on type, leukemia therapeutics market is segmented into chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant. The chemotherapy segment is expected to account for the largest share segment of the market in 2017. Chemotherapy segment further sub segmented into alkylating agents, antimetabolites, antitumor antibiotics, and others.
Top Key Players
- Eisai Co., Ltd (Japan)
- Novartis AG (Switzerland)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Bristol-Myers Squibb Company (US)
- Hoffmann-La Roche AG (Switzerland)
- Sanofi S.A. (France)
- Teva Pharmaceutical Industries Ltd (Israel)
- Amgen Inc (US)
- Takeda Pharmaceutical Company Ltd (Japan)
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global leukemia therapeutics market owing to a well-established player, innovative therapies to drive the market for leukemia, increase prevalence of leukemia, and increasing older population.
Europe is expected to hold the second largest position in the global leukemia therapeutics market. The market growth in this region is attributed to increase prevalence of leukemia.
The leukemia therapeutics market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region.
The Middle East & Africa has the least share of the leukemia therapeutics market.
Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/leukemia-therapeutics-market-7425
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
No comments:
Post a Comment